



Antiretroviral treatment indications and adherence to the German-Austrian treatment initiation guidelines in the German ClinSurv HIV Cohort between 1999 and 2016

Melanie Stecher^{1,2} · Philipp Schommers^{1,2} · Daniel Schmidt^{3,4} · Christian Kollan³ · Barbara Gunsenheimer-Bartmeyer³ · Clara Lehmann^{1,2} · Martin Platten¹ · Gerd Fätkenheuer^{1,2} · Jörg Janne Vehreschild^{1,2} · ClinSurv Study Group

Received: 11 September 2018 / Accepted: 3 November 2018
© Springer-Verlag GmbH Germany, part of Springer Nature 2018

Abstract

Purpose The aim of the study was to assess guideline adherence to combined antiretroviral therapy (ART) in the German ClinSurv HIV Cohort and the real-life impact of the Strategic Timing of Antiretroviral Therapy (START) study, to identify patients not treated as recommended by new guidelines.

Methods We used data from the multicenter ClinSurv cohort of the Robert-Koch-Institute (RKI) between 1999 and 2016. Inclusion criteria were people living with HIV/AIDS, ≥ 18 years of age and cART naïve at the first visit (FV). Adherence was defined as starting cART within 6 months of crossing the CD4⁺ T cell threshold as suggested by the German-Austrian treatment guidelines. Logistic regression was used to identify factors associated with non-adherence.

Results 11,817 patients met the inclusion criteria. We observed an overall adherence rate of 60%, in patients with treatment indication who started cART timely between 2002 and 2015. Adherence rate increased constantly, demonstrating a potential increase in patients, with treatment indication, starting cART within 6 months of presentation from 55% in 2008 to 94% in 2015. Patients reporting injection drug use (OR 2.18, 95% CI 1.70–2.95) and patients between 18 years and 39 years of age at the time of their first visit (OR 2.89, 95% CI 1.35–6.18) were identified as risk groups associated with non-adherence.

Conclusion The majority of patients below the CD4⁺ T cell count threshold of applicable guidelines initiated treatment within 6 months. We observed a slowly diminishing proportion of patients not starting cART timely. Delayed treatment was more frequent in patients reporting injection drug use.

Keywords HIV · Antiretroviral therapy · START · Treatment guidelines · Adherence

Electronic supplementary material The online version of this article (<https://doi.org/10.1007/s15010-018-1248-8>) contains supplementary material, which is available to authorized users.

✉ Melanie Stecher
melanie.stecher@uk-koeln.de

✉ Jörg Janne Vehreschild
joerg.vehreschild@uk-koeln.de

¹ Department I for Internal Medicine, University Hospital of Cologne, Cologne, Germany

² Partner Site Cologne-Bonn, German Center for Infection Research (DZIF), Cologne, Germany

³ Department of Infectious Disease Epidemiology, Robert Koch Institute, Berlin, Germany

⁴ Charité – University Medicine Berlin, Berlin, Germany

Introduction

The HIV-AIDS epidemic has fundamentally changed by the introduction of highly active antiretroviral therapy (HAART) in the late 1990s [1, 2]. The initiation of HAART, or later called combined antiretroviral therapy (cART), has led to a substantial reduction of morbidity and mortality in People living with HIV/AIDS (PLWHA) [3]. Quality of life [4] and life expectancy has improved significantly during the past two decades [3, 5]. In 2016, approximately 36.7 million people were living with HIV [6]. As of October 2017, a 20.9 million people were accessing cART [6], compared to only 7.7 million in 2010 reflecting the global efforts to treat more patients to achieve the WHO/UNAIDS 90-90-90 targets by 2020 [7]. Ever since the introduction of cART, there has been an ongoing discussion on the optimal timing

to initiate therapy due to uncertainty about risks and benefits. Adverse drug reactions [8], known side effects of some antiretroviral remedies [9], long-term toxicity [10], the prevalence of drug resistance mutations [11] have to be weighed against individual health benefits and declining rates of HIV transmission [12]. Further, public health aspects of cART have become more important due to the advancements in treatment, implementation of lifelong therapies and, therefore, increasing economic burden [13–15].

Very recently, the huge landmark trial, Strategic Timing of Antiretroviral Therapy (START) has demonstrated strong positive effects by starting cART immediately after diagnosis of HIV infection irrespective of the CD4⁺ T cell count. It seems that a longstanding scientific debate about the ideal timing of starting cART might have ended [16]. The results of the START-trial [16] as well as the TEMPRANO-trial, that showed similar results [17] are reflected in actual international guidelines in Europe, Great Britain and the US [18–20]. Consequently, the US-guidelines now recommend treating any HIV-infected patient with cART, regardless of his or her CD4⁺ T cell count at first visit (FV) [18]. In the past, the German-Austrian HIV treatment guidelines used to recommend cART initiation at lower CD4⁺ T cell count thresholds in HIV-infected individuals. The current German-Austrian guidelines are adapted at international guidelines in order to start cART immediately at FV irrespective of CD4⁺ T cell count [21–24].

Little data exist about the adherence to the treatment guidelines by physicians that treat HIV-infected individuals. This analysis aims to assess guideline adherence in Germany as found in the German ClinSurv HIV Cohort. Further, we aimed to assess the real-life impact of the START study on treatment of HIV-infected patients in Germany. The results of this study will serve as a basis for further discussion concerning cART guidelines and the importance for patients, physicians, public health and costs for the German health care system.

Methods

ClinSurv data

We performed a retrospective subgroup analysis using data from the German Clinical Surveillance of HIV Disease cohort of the Robert Koch Institute (RKI). The clinical surveillance of HIV, ClinSurv HIV is a long-term observational multi center, prospective cohort study of HIV positive patients (since 1999). The aim of this cohort study is to analyze antiretroviral treatment outcome and success over time as well as the development of AIDS-related diagnoses and death in patients with chronic HIV infection. The cohort acts as an enlargement of the national HIV surveillance in

the clinical HIV care setting. The details of the ClinSurv HIV cohort have been published elsewhere [25]. Data for this analysis were collected from 14 university hospitals and specialized HIV treatment centers. Subjects meeting the following criteria were considered for our analysis: PLWHA of the ClinSurv cohort, starting cART between 1999 and June 2016, ≥ 18 years. We excluded patients who were not treatment naïve at the time of the FV, patients without baseline data (including CD4⁺ T cell count and VL) 3 months prior to starting cART and patients who received initial therapy before 1999 (Fig. 1).

Statistical analysis

Patient characteristics at the time of their FV and the initiation of cART were displayed as absolute numbers plus percentages, medians plus interquartile ranges (IQR) or means plus 95% confidence intervals (95% CI), as appropriate. Parametric and non-parametric tests were used for normally and not-normally distributed data. VL measurements were either reported as an integer or as a measurement below the limit of quantification (< 50 , < 500 , < 1000). Therefore, the half of the limit of detection was used in 155 cases [26].

We assessed adherence according to changing treatment guidelines by defining adherence as initiating cART within 6 months of crossing the CD4⁺ T cell count threshold recommended by the applicable German-Austrian cART guidelines for each year from 2002 to 2016, categorized in recommended, consider/offer and not recommended [22, 23, 27, 28] (Supplementary Table 1). We further performed




Fig. 1 Flow chart of selected cases due to predefined inclusion and exclusion criteria

two uni- and multivariable logistic regression models, using backward elimination to identify variables that are associated with the outcome variable. Odds ratio (OR) and 95% CI were used to report the direction and strength of association.

Time-to-event parameters were estimated using Kaplan–Meier method. The primary outcome was the initiation of cART, whereas the time to event was calculated as the time from date of the FV followed until the initiation of cART. Differences between groups were analyzed and compared using the log rank test. Pairwise log rank comparisons were used to determine differences in time to event within each group. To counter multiple comparisons, we applied a Bonferroni correction [29]. We further used a Cox regression model to estimate the proportional hazard and 95% CI to display the direction and strength of the association between variables of interest, with the number of months from the FV until the initiation of cART as time scale.

Based on exploratory analysis, we categorized VL, CD4⁺ T cell count, age and the year of the FV. VL categories were defined as follows: < 10,000, 10,000–99,999, ≥ 100,000. CD4⁺ T cell categories as < 200, 200–349, 350–499 and ≥ 500. Age groups 18–39, 40–69 and ≥ 70. Year of FV: before 2002, 2002–2007, 2008–2014 and 2015–2016. Symptomatic-HIV disease stages, including diagnosis reported within 1 month before the FV, were categorized based on the disease classification System of the Center for disease control and prevention (CDC). Self-reported HIV risk behavior were categorized in men having sex with men (MSM), people with injection drug use (PWID), heterosexuals (HTS), people from an endemic area (countries with a HIV prevalence > 1%), and others (including infected people due to prenatal and perinatal infection, blood transfusion and blood product and people with hemophilia (PwH) and unknown. Analyses were accomplished by using Stata (Stata Statistical Software: Release 14. College Station, TX: StataCorp LP).

Results

Study population

Data on 25,353 patients enrolled in the ClinSurv cohort between 1999 and June 2016 were available. Our final analysis was performed on 11,817 patients who met the inclusion criteria (Fig. 1). Patient characteristics, demographic and clinical data are shown in Table 1. The patient population was predominantly male (79.3%, $n=9373$) from a European country (80.6%, $n=9520$) with a median age of 37 years (IQR 30–45), at time of the FV. The greatest amount of patients started treatment within 6 months (65%), followed by 12 (7%) and 18 (5%) months after first presentation. The median VL and CD4⁺ T cell count at the time of the FV was 66,069 copies/ml (IQR 15,500–233,000) and 275

cells/mm³ (IQR 109–455), compared to 88,550 copies/ml (IQR 25,119–277,042) and 188 cells/mm³ (IQR 86–331) at the start of cART. The initial cART regime contained 39.9% (4711) NRTI/PI/boost, 36.2% (4282) NRTI/NNRTI and 8.7% (1,029) NRTI/II. A total of 1063 (9.0%) and 1008 (8.5%) patients were symptomatic according to CDC category B and C, respectively 1 month before and at the time of the FV [30]. Overall, 639 (5.5%) deaths have been reported between 1999 and June 2016.

Adherence to treatment initiation guidelines

Adherence to the German-Austrian cART initiation guidelines is displayed in Fig. 2, comparing patients with and without treatment indication to start cART regarding CD4⁺ T cell count based on the applicable treatment initiation guidelines from 2002 until 2015 [21–24, 27, 28].

We observed an overall adherence rate of 59.7%, in patients with treatment indication who started cART timely between 2002 and 2015. Since 2008, the amount of patients who started cART within 6 months increased constantly from 53 to 75% in 2014. In 2015, more than 94% of all patients initiated cART as recommended within 6 months after their FV. Simultaneously, the overall proportion of patients with treatment indication who did not start therapy though recommended declined from 25% in 2002 to 8% in 2014.

Non-adherence to treatment initiation guidelines

To identify factors that are possibly associated with non-adherence, we conducted two univariate and multivariable logistic regression models. In the first model, we analyzed non-adherence to treatment guidelines in patients without treatment indication who initiated cART within 6 months after their FV (Supplementary Table 2). In the second model, we examined non-adherence in patients with treatment indication who did not initiate cART within 6 months after the FV (Table 2). We identified clinical and geographical characteristics summarized in Supplementary Table 2 and Table 2. Following key findings were identified in the multivariable analyses.

Patients with their first visit in 2002–2007 and 2008–2014 were significantly associated with a delayed initiation of cART (OR 9.66, 95% CI 6.11–15.26 and OR 5.08, 95% CI 3.21–8.03) (vs first visit in 2015–2016), as well as patients between 18 and 39 years of age at the time of their first visit (OR 2.89, 95% CI 1.35–6.18). Delay in treatment initiation was significantly more likely in patients reporting injection drug use (OR 2.18, 95% CI 1.70–2.95) and patients with a clinical disease stage A&B (OR 1.76, 95% CI 1.21–2.57) (Table 2). Moreover, female patients and patients from Asia, Australia or New Zealand were significantly more likely to

Table 1 Characteristics at the time of the first visit (FV) of 11,817 patients included in the subgroup analysis of the ClinSurv cohort

Patient characteristics	No of patients (<i>n</i> = 11,817)	(%)
Gender		
Female	2444	20.7
Male	9373	79.3
Risk group*		
MSM	5935	50.2
PWID	770	6.5
HTS	1939	16.4
Endemic area	1620	13.7
Other	1553	13.1
Country of origin		
Europe	9520	80.6
North-Eastern Africa	96	0.8
Sub-Saharan Africa	1367	11.6
Asia, Australia and New Zealand	391	3.3
North and Latin-American	245	2.1
Missing	198	1.7
CD4 ⁺ T cell count at FV	Median: 275	IQR: 109–455
<200	4514	38.2
200–349	2700	22.8
350–499	2200	18.6
≥500	2403	20.3
Viral load (copies/μl)	Median: 66,069	IQR: 15,500 – 233,000
<10,000	2249	19.0
10,000–99,999	4352	36.8
≥100,000	4680	39.6
Missing	536	4.5
Age (groups)	Median: 37	IQR: 30–45
18–39	2796	23.7
40–69	8410	71.2
≥70	611	5.2
Year of FV	Median: 2007	IQR: 2002–2011
<2001	2266	19.2
2002–2007	4285	36.3
2008–2014	4.824	40.8
2015–2016	442	3.7
Therapy initiation after FV (months)	Median 1	IQR: 0–15
<6	7657	64.8
6–11	791	6.7
12–17	577	4.9
18–24	437	3.7
≥24	2,355	19.9
CDC category at FV**		
A	38	0.3
B	1063	9.0
C	1008	8.5
No diagnosis or missing	9708	82.2
cART regime		
NRTI/PI/boost	4711	39.9
NRTI/NNRTI	4282	36.2
NRTI/II	1029	8.7
NRTI	461	3.9


Table 1 (continued)

Patient characteristics	No of patients (<i>n</i> = 11,817)	(%)
NRTI/II/boost	294	2.5
Others	1040	8.8

*MSM, men who have sex with men; HTS, heterosexual; PWID, persons who inject drugs; endemic area, people from countries with a HIV prevalence > 1%; others, including infected people due to prenatal and perinatal infection, blood transfusion and blood product and people with hemophilia (PwH) and unknown

**The HIV disease classification (Center for Disease Control and Prevention (CDC) categories A, B and C) including diagnosis reported within 1 month before the First Visit (FV)

Fig. 2 Adherence to the German-Austrian cART guidelines applicable for each year, considering patients with treatment indication due to the CD4⁺ T cell count thresholds (including additional therapy recommendations such as CDC stage C, > 50 years of age, viral load > 100,000 and without treatment indication who initiated cART within the first 6 months after the first visit (FV). *Not recommended, but acceptable according to experts' opinion



initiate therapy even though the guidelines recommended otherwise (OR 1.65, 95% CI 1.07–2.57 and OR 2.78, 95% CI 1.05–7.38, respectively) (Supplementary Table 2).

Time to initiate cART

Time to event analysis indicated strong prognostic factors regarding the time to initiate cART within 6 months. We observed significant associations with an earlier start of cART after FV regarding lower CD4⁺ T cell counts ($p < 0.001$), higher VL ($p < 0.001$), older age ($p < 0.001$), the HIV disease stages ($p < 0.001$) a more current FV in the period of < 2001–2015 ($p < 0.001$), region of origin ($p < 0.001$) and reported risk groups ($p < 0.001$). Pairwise comparison revealed significant differences among subgroups for early initiation of cART (Supplementary Table 3). We further calculated a multivariable Cox regression model using backward elimination to identify associating factors to start cART. The adjusted Hazard Ratios (HR) for the association of factors at baseline with causes to start cART are presented in (Table 3). Patients with a higher baseline CD4⁺ T cell count were significantly less likely to start cART compared to patients with a CD4⁺ T cell count < 200 (CD4⁺ T cell count ≥ 500 HR 0.37; 95% CI 0.30 – 0.45;

350–499 HR 0.25; 95% CI 0.19 – 0.31; 200–349 HR 0.57; 95% CI 0.49–0.66). Patients with their FV in the time period from 2008 to 2014 and 2015–2016 were significantly more likely to initiate cART compared to patients with their first visit before 2001 (HR 1.29; 95% CI 1.14–1.82 and HR 1.44; 95% CI 1.14–1.82, respectively). Same trends were observed in patients with a symptomatic HIV disease condition (CDC category C) at the time of the FV (HR 1.08; 95% CI 0.98–1.18).

Discussion

The main goal of our study was to evaluate adherence to treatment guidelines in Germany over a 17-year period with multiple shifts in recommended thresholds for treatment initiation. To that end, we retrospectively analyzed data of the ClinSurv cohort, including epidemiological and medical data from 11,817 PLWHA, treated in 14 major HIV treatment centers and university hospitals throughout Germany. To our knowledge, this is the first study focusing on treatment routines in the context of contemporary guidelines of German clinicians.

Table 2 Univariate and multivariable logistic regression model for non-adherence [patients with treatment indication who did not start therapy within 6 months after the first visit (FV)] displayed with OR and 95% CI, adjusted for gender, region of origin, year of FV, HIV disease classification (Center for Disease Control and Prevention (CDC) categories A, B & C) at FV ($n=7964$)

	Univariate analysis		Multivariable analysis**	
	OR (95% CI)	<i>p</i> value*	OR (95% CI)	<i>p</i> value*
Total				
FV year				
2002–2007	9.07 (5.81–14.17)	< 0.001	9.66 (6.11–15.26)	< 0.001
2008–2014	4.88 (3.13–7.64)	< 0.001	5.08 (3.21–8.03)	< 0.001
2015–2016				
Gender				
Male				
Female	0.80 (0.71–0.91)	< 0.001		
Risk				
HTS				
MSM	1.15 (1.01–1.32)	0.025	1.12 (0.75–1.67)	0.566
PWID	1.44 (1.15–1.80)	0.001	2.18 (1.70–2.95)	0.013
ENDEMIC*	0.64 (0.53–0.76)	< 0.001	0.60 (0.16–2.31)	0.466
Others/unknown	0.69 (0.58–0.83)	< 0.001	0.66 (0.37–1.17)	0.160
Age (groups)				
18–39	1.39 (1.12–1.71)	0.002	2.89 (1.35–6.18)	0.006
40–69	1.10 (0.99–1.34)	0.329	1.40 (0.73–2.69)	0.306
≥ 70				
Region of origin				
Europe				
North-East Africa	0.52 (0.29–0.93)	0.028		
Sub-Saharan Africa	0.60 (1.51–1.71)	< 0.001		
Asia, Australia and New Zealand	0.54 (0.40–0.72)	< 0.001		
North and Latin America	0.87 (0.63–1.21)	0.416		
CDC category				
A&B	1.69 (1.22–2.36)	0.002	1.76 (1.21–2.57)	0.003
C				

**p* values (< 0.05) in bold depict significant results

**Multivariable model adjusted for gender, region of origin, and CDC category

We found that the majority of patients below the CD4⁺ T cell count threshold of applicable guidelines from 2002 to 2016 [22, 23, 27, 28] received treatment within 6 months of presentation. Our analysis revealed that adherence increased constantly since 2008 from 55% to 94% in 2015. This finding might reflect that patients' willingness to adhere to the recent guidelines increased and that patients reached a conscious awareness that therapy guidelines are desired and beneficial. In addition, the introduction of more durable and patient-friendly drugs classes, i.e. integrase inhibitors or next generation protease inhibitors, may have improved adherence to treatment guidelines among patients and clinicians. Our results correspond to the results of Schmidt et al. [31], who observed an increase in PLWHA receiving cART in Germany from 2006 to 2013. Moreover, the results show that the amount of patients on cART increased by 6% from 2014 to 2015, which is a more pronounced increase compared to previous years (Fig. 2). We hypothesize that especially the newly presenting patients were affected by

the preliminary- [32, 33] and final results of the START trial [16], resulting in an update of treatment guidelines in 2015 [21].

Although, our analyses revealed that adherence to treatment initiation guidelines increased over time, we identified risk groups with suboptimal adherence to treatment initiation guidelines. PWID and people with younger age did not start therapy timely despite treatment indication. These findings are possibly linked to the results of our previous study, which elucidated that the risk group of PWID represent a source of onward DRM transmission among therapy naïve individuals in the Cologne-Bonn region in Germany highlighting the need to implement prevention interventions targeting the risk group of PWID [34]. Similar trends, demonstrating that injection drug use negatively affects adherence and testing behavior, have already been observed in previous studies [35, 36]. Anticipated stigma, a low socioeconomic status and poor access to medical care can also negatively affect testing behavior and treatment adherence

Table 3 Cox regression model. Hazard ratios (HRs) and 95% confidence intervals (CI) associated with starting cART from cox model adjusted for gender, country of origin, HIV disease classification (Center for Disease Control and Prevention (CDC) categories A, B & C) at time of the First Visit (FV), year of FV, CD4 cell count and VL at FV ($n = 11,817$)

	HR (95% CI)	<i>p</i> value*
Total		
Gender		
Female		
Male	1.06 (0.94–1.16)	0.290
VL FV		
< 10,000		
10,000–99,999	0.94 (0.80–1.10)	0.420
≥ 100,000	1.02 (0.88–1.17)	0.835
CD4 ⁺ T cell count (cells/μl) at FV		
< 200		
200–349	0.57 (0.49–0.66)	< 0.001
350–499	0.25 (0.19–0.31)	< 0.001
≥ 500	0.37 (0.30–0.45)	< 0.001
FV year		
< 2001		
2002–2007	1.02 (0.90–1.15)	0.420
2008–2014	1.29 (1.14–1.82)	< 0.001
2015–2016	1.44 (1.14–1.82)	0.002
CDC category at FV		
A&B		
C	1.08 (0.98–1.18)	0.092

**p* values (< 0.05) in bold depict significant results

[37]. In Addition, we identified that female patients were significantly more likely to initiate therapy even though the guidelines recommended otherwise. This might be associated with the amount of pregnant women or women of child-bearing age, which could not have been taken into account in our analysis. Factors most strongly associated with the initiation of cART in the Cox regression model were the year of the FV and the CD4⁺ T cell count, reflecting adherence to the applicable treatment guidelines (Table 3).

Our study has limitations based on the used methodology and data source. We identified inconsistencies regarding the documentation of the VL and CD4⁺ T cell count. Values were either recorded directly or as a measurement below the limit of quantification (< 50, < 500). To get consistent results, we used the half of the limit of detection in 155 cases for our analysis, a common method used in prior studies [26]. Our results might be biased, as it is less likely that individuals from hard to reach populations were included in our dataset. Among these populations, the initiation of care, the overall use of cART and the attitude towards starting cART are less frequent [38]. Thus, HIV infections of these populations cannot be reported. However, our study

population was comparable with the population of HIV PLWHA in Germany [39] as the ClinSurv cohort capture a fairly representative sample population of HIV patients in care [40]. The data of the ClinSurv cohort was not fully captured for 2015–2016; consequently data from 2015 to 2016 are comparable to a limited extent only and need to be interpreted with caution.

In conclusion, we found evidence that adherence to treatment initiation guidelines increased constantly since 2008. The majority of patients below the CD4⁺ T cell count of applicable guidelines received treatment within 6 months of presentation and the number of patients initiating cART, despite the CD4⁺ T cell count thresholds of applicable cART guidelines, increased significantly. There was a slowly diminishing proportion of patients not starting cART timely, despite a CD4⁺ T cell count under the recommended threshold. PWID were identified as risk groups associated with non-adherence, which support the need to improve access to treatment especially among the risk group of PWID. Further analyses must aim at identifying barriers and reasons for not starting treatment to educate measures towards increasing the share of patients with timely treatment initiation.

Our study has demonstrated customary treatment strategies by HIV practitioners in Germany in the context of developing evidence and guidelines and addresses perspectives for the future development of cART strategies and the progress towards the UNAIDS 90-90-90 [7]. We established that changes of treatment guidelines led to a substantial increase of patients receiving cART. In the future, it will be important to develop effective interventions towards better coverage of vulnerable patient groups such as PWID by guidelines and individual therapeutic considerations.

Acknowledgements This study was funded by the German Center for Infection Research. Initial results of this study were presented at the ‘21st International Workshop on HIV and Hepatitis Observational Databases’ in Lisbon, Portugal 2016, Abstract no: 109.

Author contributions JV and MS designed the study, analyzed and interpreted the data. MS drafted the primary draft of the manuscript. BG, CK and DS provided data, and contributed critically important ideas on how to interpret the data. PS, BG, CK, DS, MP, CL and GF revised the manuscript critically for important intellectual content. All authors approved the final version of the manuscript.

Compliance with ethical standards

Conflict of interest This study is a project within the TP-HIV by the German Centre for Infection Research (DZIF) (NCT02149004). We declare that all authors have no conflicts of interest.

References

1. Murray CJ, Vos T, Lozano R, et al. Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions,

- 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010. *Lancet*. 2012;380:2197–223.
2. Vos T, Flaxman AD, Naghavi M, et al. Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010. *Lancet*. 2012;380:2163–96.
 3. The Antiretroviral Therapy Cohort Collaboration. Survival of HIV-positive patients starting antiretroviral therapy between 1996 and 2013: a collaborative analysis of cohort studies. *Lancet HIV*. 2017;4:e349–e56.
 4. Walensky RP, Paltiel AD, Losina E, et al. The survival benefits of AIDS treatment in the United States. *J Infect Dis*. 2006;194:11–9.
 5. May M, Gompels M, Delpech V, et al. Impact of late diagnosis and treatment on life expectancy in people with HIV-1: UK Collaborative HIV Cohort (UK CHIC) Study. *Br Med J*. 2011;343:11.
 6. UNAIDS. Fact sheet—latest statistics on the status of the AIDS epidemic. http://www.unaids.org/sites/default/files/media_asset/UNAIDS_FactSheet_en.pdf. Accessed Feb 2018.
 7. UNAIDS. 90-90-90—an ambitious treatment target to help end the AIDS epidemic. Geneva: Joint United Nations; 2014.
 8. Camacho R, Teofilo E. Antiretroviral therapy in treatment-naïve patients with HIV infection. *Curr Opin HIV AIDS*. 2011;6:3–11.
 9. Brouwer ES, Napravnik S, Eron JJ Jr, et al. Effects of combination antiretroviral therapies on the risk of myocardial infarction among HIV patients. *Epidemiology*. 2014;25:406–17.
 10. Grinsztejn B, Hosseinipour MC, Ribaud HJ, et al. Effects of early versus delayed initiation of antiretroviral treatment on clinical outcomes of HIV-1 infection: results from the phase 3 HPTN 052 randomised controlled trial. *Lancet Infect Dis*. 2014;14:281–90.
 11. Hofstra LM, Sauvageot N, Albert J, et al. Transmission of HIV drug resistance and the predicted effect on current first-line regimens in Europe. *Clin Infect Dis*. 2016;62:655–63.
 12. Phillips AN, Cambiano V, Miners A, et al. Potential impact on HIV incidence of higher HIV testing rates and earlier antiretroviral therapy initiation in MSM. *Aids*. 2015;29:1855–62.
 13. Stoll M, Claes C, Schulte E, Korner T, von der Schulenburg JM, Schmidt R. [Public health economic aspects of antiretroviral therapy. Can we afford to do less?]. *MMW Fortschr Med*. 2000;142:45–9.
 14. Schackman BR, Gebo KA, Walensky RP, et al. The lifetime cost of current human immunodeficiency virus care in the United States. *Med Care*. 2006;44:990–7.
 15. Hutchinson AB, Farnham PG, Dean HD, et al. The economic burden of HIV in the United States in the era of highly active antiretroviral therapy: evidence of continuing racial and ethnic differences. *J Acquir Immune Def Syndrom*. 1999;2006;43:451–7.
 16. Lundgren JD, Babiker AG, Gordin F, et al. Initiation of antiretroviral therapy in early asymptomatic HIV infection. *N Engl J Med*. 2015;373:795–807.
 17. The TEMPRANO ANRS 12136 Study Group. A trial of early antiretrovirals and isoniazid preventive therapy in Africa. *N Engl J Med*. 2015;373:808–22.
 18. Panel on Antiretroviral Guidelines for Adults and Adolescents. US-Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. https://aidsinfo.nih.gov/contentfiles/lvguidelines/adult_andadolescentgl.pdf. Accessed January 2018.
 19. Waters L, Ahmed N, Angus B, et al. BHIVA guidelines for the treatment of HIV-1-positive adults with antiretroviral therapy 2015 (2016 interim update). <http://www.bhiva.org/documents/Guidelines/Treatment/2016/treatment-guidelines-2016-interim-update.pdf>. Accessed Oct 2017.
 20. EACS. European Guidelines for treatment of HIV-positive adults in Europe 8.0. http://www.eacsociety.org/files/guidelines_8.0-english-revised_20160610.pdf. Accessed Oct 2017.
 21. Deutsche AIDS-Gesellschaft, Österreichische AIDS-Gesellschaft. Deutsch-Österreichische Leitlinien zur antiretroviralen Therapie der HIV-Infektion. <http://www.daignet.de/site-content/hiv-therapie/leitlinien-1>. Accessed Oct 2017.
 22. Deutsche AIDSG. Deutsch-Österreichische Leitlinien zur antiretroviralen Therapie der HIV-Infektion, 2014.
 23. Deutsche AIDS-Gesellschaft, Österreichische AIDS-Gesellschaft. Deutsch-Österreichische Leitlinien zur antiretroviralen Therapie der HIV-Infektion, 2012.
 24. Deutsche AIDS-Gesellschaft, Österreichische AIDS-Gesellschaft. Deutsch-Österreichische Leitlinien zur Therapie der HIV-Infektion 2010, 2010.
 25. Batzing-Feigenbaum J, Kollan C, Kuhne A, Matysiak-Klose D, Gunsenheimer-Bartmeyer B, Hamouda O. Cohort profile: the German ClinSurv HIV project—a multicentre open clinical cohort study supplementing national HIV surveillance. *HIV Med*. 2011;12:269–78.
 26. Marschner IC, Betensky RA, DeGruttola V, Hammer SM, Kuritzkes DR. Clinical trials using HIV-1 RNA-based primary endpoints: statistical analysis and potential biases. *J Acquir Immune Def Syndrom Hum Retrovirol*. 1999;20:220–7.
 27. Deutsche AIDS-Gesellschaft, Österreichische AIDS-Gesellschaft. Deutsch-Österreichische Leitlinien zur antiretroviralen Therapie der HIV-Infektion 2002. *Dtsch Med Wochenschr* 2003; (128): S7-S18.
 28. Deutsche AIDS-Gesellschaft, Österreichische AIDS-Gesellschaft. Deutsch-Österreichische Leitlinien zur antiretroviralen Therapie der HIV-Infektion 2008. 2008.
 29. Armstrong RA. When to use the Bonferroni correction. *Ophthalmic Physiol Opt*. 2014;34:502–8.
 30. Centers for Disease Control and Prevention. revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. *MMWR Recommend Rep Morbid Mortal Week Rep Recommend Rep* 1992. 1993;41:1–19.
 31. Schmidt D, Kollan C, Stoll M, et al. From pills to patients: an evaluation of data sources to determine the number of people living with HIV who are receiving antiretroviral therapy in Germany. *BMC Public Health*. 2015;15:252.
 32. INSIGHT START Study Group. Strategic timing of antiretroviral treatment (START) study primary results. In: 8th IAS conference on HIV pathogenesis treatment and prevention. Vancouver, Canada, 2015.
 33. Danel C, Moh R, Gabillard D, et al. Early ART and IPT in HIV-infected African adults with high CD4 Count (Temprano Trial). Conference on retroviruses and opportunistic infections. Seattle, WA, USA, 2015.
 34. Stecher M, Chaillon A, Eis-Hubinger AM, et al. Pre treatment HIV-1 drug resistance in transmission clusters of the Cologne-Bonn Region, Germany. *Clin Microbiol Infect* 2018.
 35. Azar P, Wood E, Nguyen P, et al. Drug use patterns associated with risk of non-adherence to antiretroviral therapy among HIV-positive illicit drug users in a Canadian setting: a longitudinal analysis. *BMC Infect Dis*. 2015;15:193.
 36. Arnsten JH, Li X, Mizuno Y, et al. Factors associated with antiretroviral therapy adherence and medication errors among HIV-infected injection drug users. *J Acquir Immune Def Syndrom* 1999;2007; 46:64–71.
 37. Bolsewicz K, Debattista J, Valley A, Whittaker A, Fitzgerald L. Factors associated with antiretroviral treatment uptake and

- adherence: a review. Perspectives from Australia, Canada, and the United Kingdom. *AIDS Care*. 2015;27:1429–38.
38. Rebolledo P, Kourbatova E, Rothenberg R, del Rio C. Factors associated with utilization of HAART amongst hard-to-reach HIV-infected individuals in Atlanta, Georgia. *J AIDS HIV Res (Online)*. 2011;3:63–70.
 39. Robert-Koch-Institut. *Epidemiologisches Bulletin* 45, page 476–483. http://www.rki.de/DE/Content/Infekt/EpidBull/Archiv/2015/Ausgaben/45_15.pdf?__blob=publicationFile. Accessed Jun 2017.
 40. Vourli G, Pharris A, Cazein F, et al. Assessing the representativeness of European HIV cohort participants as compared to HIV surveillance data. In: *Control ECfDPA. HepHIV*. Malta, 2017.